Table 1. Results of survey regarding timing of endoscopic procedures during COVID-19 pandemic.

Indication	Most common decision	Percentage of highest votes, % (n)
Gastrointestinal bleeding
Evaluation of melena	Everyone should have endoscopy	44.5 (438)
Evaluation of hematochezia	Scope patients with hemodynamic instability	61.9 (389)
Evaluation of upper gastrointestinal bleeding in cirrhosis	Everyone should have EGD	87.6 (410)
Procedures for common gastrointestinal signs and symptoms	EGD for acute onset of dysphagia	55.8 (407)
Evaluation of dysphagia
Evaluation of iron deficiency anemia	Defer endoscopic evaluation for now	58.3 (48)
Evaluation of abnormal weight loss	Defer endoscopic evaluation for now	84.7 (359)
Concerns for dysplasia/cancer
Colonoscopy for positive FIT/Fecal-FIT DNA (Cologuard) testing	Defer procedure for now	70 (834)
Ulcerative colitis with dysplasia	Defer chromoendoscopy for now	52.6 (19)
EMR for colon polyps	Defer colonoscopy for now	63.3 (355)
ESD of early gastric cancer	Defer EGD for now	58.5 (340)
Endoscopic therapy of dysplastic Barrett's esophagus	Defer EGD for now	50.4 (421)
Evaluation of double duct sign with EUS	Defer EUS for now	53.5 (368)
Evaluation of ampullary adenoma	Defer endoscopic resection for now	53.5 (383)
Benign [pancreatobiliary indications]
Evaluation of choledocholithiasis	ERCP only if abdominal pain/jaundice	35.7 (338)
Elective exchange of biliary stenting	Defer ERCP for now	44.1 (59)
Elective removal of pancreatic stent	Defer EGD/ERCP for now	66 (50)

EGD, esophagogastroduodenoscopy; FIT, fecal immunochemistry testing; EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissection; EUS, endoscopic ultrasound; ERCP, endoscopic retrograde cholangiopancreatography